Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Celltrion gains Australian approval for three biosimilars in ophthalmology and bone disease Celltrion secures TGA endorsement ...

South Korea’s pharmaceutical giant Celltrion said Thursday it has received regulatory approvals for three biosimilars in ...

Regeneron Pharmaceuticals (REGN): Given a six-month delay for its high dose Eylea syringe to treat age-related macular degeneration, we believe the stock will have a competitive disadvantage until ...

Regulatory progress continues, with a positive CHMP recommendation for the VYVGART pre-filled syringe in the EU and ... Key products like EYLEA, Libtayo, and Dupixent propelled the company ...

Learn more about whether Alvotech or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Dupixent is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available ... the patent litigation and other related proceedings relating to EYLEA® ...